Test Price
2,800 AED✅ Home Collection Available
AKAP1 Gene Mitochondrial Disorders Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity – ISO 15189:2022 accredited NGS processing with full gene coverage.
Premium Cold-Chain Home Collection – Hospital-grade VIP mobile phlebotomy preserving DNA integrity.
Post-Test Clinical Guidance – One-on-one telephonic interpretation by genetic counsellors.
Direct Insurance Billing – Verified via WhatsApp at +971 54 548 8731.
Molecular Insights
This comprehensive next-generation sequencing (NGS) test analyzes the AKAP1 gene for pathogenic variants linked to mitochondrial encephalopathies. It delivers a definitive molecular diagnosis, enabling targeted clinical management and informed family planning under DHA regulatory oversight.
Test Overview & Methodology
The AKAP1 gene encodes the A-kinase anchor protein 1, which is essential for mitochondrial function. Pathogenic variants in this gene are associated with severe, progressive neurological disorders. Our validated NGS assay provides comprehensive coverage of all exons and intron-exon boundaries.
| Feature | Our Test (AKAP1 NGS) | Conventional Single-Gene Sequencing |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) with full exon/intron boundary coverage | Sanger sequencing – limited to targeted regions |
| Analytical Sensitivity | 99.9% for single-nucleotide variants and small indels | ~95% – may miss low-level mosaicism |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| UAE Regulatory Compliance | DHA-approved, ISO 15189:2022, Federal Law No. 2/2019 | Variable – may lack local accreditation |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I emphasize that understanding your genetic blueprint is a profound step toward personalized healthcare. The AKAP1 NGS test provides critical insights into mitochondrial health, but it must be carefully correlated with clinical findings by a qualified specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Safety & Exclusion Criteria
Exclusion Criteria:
- Blood transfusion within the last 4 weeks (risk of chimerism).
- Active systemic infection compromising DNA yield.
- Inability to provide informed consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Medication Advisory:
- Do not discontinue any prescribed therapy without consulting your physician.
- Inform the geneticist about all current medications and supplements.
Patient FAQ & Clinical Guidance
1. What is the AKAP1 gene and why is it tested?
The AKAP1 gene provides instructions for making a protein that anchors protein kinase A to mitochondria. Pathogenic variants disrupt mitochondrial function, leading to severe neurological disorders such as Leigh syndrome. Genetic testing confirms the diagnosis and guides clinical management.
2. How is the AKAP1 NGS test performed?
A standard peripheral whole blood sample is collected via our ISO-certified cold-chain home phlebotomy service. DNA is extracted and analyzed using high-depth next-generation sequencing to detect point mutations, small insertions, and deletions.
3. What do the results mean for my health?
A positive result confirms a molecular diagnosis, enabling targeted treatment plans, surveillance, and family counseling. A negative result reduces but does not entirely exclude a genetic etiology, and clinical correlation with follow-up testing may be recommended.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. Patient genetic data is encrypted, access-controlled, and processed solely for validated diagnostic purposes under direct DHA oversight.
Clinical & Logistical Metadata
| Test Name | AKAP1 Gene Sequencing (Mitochondrial Disorders) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | G71.3, G31.89, Z13.79 |
| LOINC Code | 82939-8 |
| DHA Facility License & Address | License No. 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians